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COMPETING ON QUALITY: IDENTIFYING PERFORMANCE INDICATORS
AND OUTCOMES FOR PEDIATRIC STEM CELL TRANSPLANTATION
Quinn, M.A. University of California San Francisco Children’s Hospi-
tal, San Francisco, CA.
Background. The awareness and commitment to quality in
health care is supported by organizations that guide the standards
of excellence for hospitals nationwide. These standards, albeit
necessary and effective, are broad and not directly applicable to the
processes of small specialty programs such as pediatric stem cell
transplantation. In an attempt to customize national standards to
daily practice, the UCSF Pediatric Bone Marrow Transplant
(PBMT) team developed a unique quality program to achieve a
standard of excellence that would be recognized by the transplan-
tation community and the patients it serves. Methods. Implemen-
tation of a quality strategy involves identifying appropriate perfor-
mance indicators and predicted outcomes. The PBMT team was
solely responsible for accomplishing this task. The Foundation for
the Accreditation of Cellular Therapy (FACT) provided a forum
for the team to experience this process through the development of
a Quality Management Plan. Results. The UCSF PBMT team
collectively identiﬁed 5 indicators of quality by which to measure
performance (ie, morbidity/mortality, engraftment, aGvHD, fun-
gal infections, and patient satisfaction). The team chose indicators
that correlated with the main points of data that all transplantation
programs collect and report to the IBMTR. The fundamental
challenge is the inability to pool a sample size that demonstrates
statistical signiﬁcance in any of the performance categories for
children. To compensate for the lack of benchmark data available
in pediatric stem cell transplantation, the program collected its
own data over a 4-year period and compared results to current
literature. After verifying that their data were consistent with
published data, the team chose to use it to follow future trends and
initiate investigation when data points fall outside the expected
range. Conclusion. The goal of quality management is optimal
patient outcome and transplantation experience. Through the im-
plementation of quality indicators and measurable outcomes, the
UCSF PBMT team functions in a continuous quality environment
that seeks to ensure superior delivery of care and patient satisfac-
tion.
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FACTORS INFLUENCING CANCELLATION OF AN ALLOGENEIC BONE
MARROW TRANSPLANTATION: A SINGLE-CENTER STUDY
Lanther, T., Sengelov, H. National University Hospital, Rigshospitalet,
Copenhagen, Denmark.
Transplantation coordinators use substantial amount of time and
effort when an allogeneic transplantation is cancelled or post-
poned. The objective of this study is to describe the reasons for
cancellation of the stem cell transplantations at our center.
In the period January 1, 2003 to September 30, 2004, a total of
144 patients were referred to the Bone Marrow Transplant Centre
Copenhagen for allogeneic stem cell transplantation. Of these 144,
97 patients (67%) were referred for myeloablative stem cell trans-
plantation (M-SCT) and 47 (33%) were referred for nonmyelo-
ablative stem cell transplantation (NM-SCT). Thirty-four patients
were children, all of whom were referred for M-SCT. Of this
cohort of 144 patients, 42 (29%) had their ﬁrst planned transplan-
tation cancelled, 24 patients were never transplanted, and 18 pa-
tients were transplanted later. The distribution by disease is given
in Table 1.
Of the patients referred to M-SCT, a matched unrelated donor
(MUD) was identiﬁed in 70%, and for the patients referred to
NM-SCT a MUD was identiﬁed in 52%. In the cancelled cohort,
84% of the M-SCTs and 59% of the NM-SCTs were MUD
transplantation. SCT was cancelled due to 3 causes: patient-related
causes in 33 patients (79%) (17 M-SCT, 16 NM-SCT), donor-
related causes in 8 patients (19%) (7 M-SCT, 1 NM-SCT), and
other causes in 1 patient (2%) (M-SCT).
Among the patient-related causes, relapse ocurred in 20 patients
(61%), infection in 6 (18%), and patient decline in 7 (21%). Of the
20 patients with relapse, 11 (55%) were scheduled to receive a SCT
from a MUD. Of the 97 patients referred for M-SCT, 17% were
cancelled due to patient-related causes. Of the 47 patients referred
for NM-SCT, 34% were cancelled due to patient-related causes.
In the group of patients cancelled because of donor issues, 88%
were scheduled for a MUD.
Conclusion. The main reason for cancellation is patient-related
circumstances; and relapse is recorded most frequently. Patients
who are referred with a MUD are at higher risk for being cancelled
due to either patient-related or donor-related reasons. The can-
celled/postponed patients are distributed equally within the differ-
ent disease groups.
Referred % Cancelled %
M-SCT 97 67% 25 60%
NM-SCT 47 33% 17 40%
Total 144 100% 42 100%
ALL 37 26% 9 21%
AML 41 28% 10 24%
MDS 15 10% 6 14%
CML 7 5% 2 5%
AA 3 2% 1 2%
MM 5 3% 2 5%
Lymphoma 22 15% 6 14%
Other 14 10% 6 14%
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IMPACT OF MULTIDISCIPLINARY CARE IN IMPROVING OUTCOMES IN
MULTIPLE MYELOMA PATIENTS RECEIVING OUTPATIENT AUTOLO-
GOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
Atmar, J.S., Shah, H.B., Nash, V. University of Texas M.D. Anderson
Cancer Center, Houston, TX.
Multiple myeloma is a disease characterized by the proliferation
of malignant plasma cells and subsequent overabundance of mono-
clonal paraprotein. It accounts for 10% of all hematologic malig-
nancies. Until recently, prognosis was poor, with a median survival
of approximately 3 years. In recent years, new therapies have been
developed that have signiﬁcantly impacted prognosis and increased
the length of survival. High-dose chemotherapy with autologous
peripheral blood stem cell transplantation (PBSCT) has been
proven efﬁcacious, resulting in both increased rates of survival and
time to progression. As autologous PBSCT becomes more com-
mon, the trend has been to perform these procedures on an
outpatient basis. Our institution now performs approximately 150
PBSCTs for multiple myeloma patients annually. Of these, half
receive their conditioning regimen and peripheral blood infusion
as outpatients. Historically, 60% of outpatients treated at our
institution have required admission to the hospital for treatment-
related toxicities. We will conduct a retrospective review of the
treatment courses of 30 patients treated with standard of care
melphalan (200 mg/m2) followed by PBSCT between March 2000
and February 2004. Working with a multidisciplinary team, in-
cluding a registered nurse, PharmD, and nurse practitioner, we
developed and implemented supportive care measures with the
goal of decreasing admission rates due to toxicity by 50%. We will
compare these data with the outcomes of 30 similar patients who
were treated after initiation of our supportive measures.
95BB&MT
